XML 151 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of significant accounting policies (Details) - USD ($)
9 Months Ended
Aug. 20, 2024
Jul. 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Aug. 30, 2024
Dec. 31, 2023
Debt Instrument [Line Items]            
Total debt     $ 700,800,000     $ 868,400,000
Proceeds from sale of business     110,200,000 $ 270,200,000    
Cash and cash equivalents     149,900,000 $ 87,800,000   $ 111,700,000
Jansen Pharmaceuticals, Inc.            
Debt Instrument [Line Items]            
Proceeds from legal settlements   $ 50,000,000 50,000,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | RSDL            
Debt Instrument [Line Items]            
Proceeds from sale of business   $ 75,000,000 75,000,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baltimore-Camden Facility            
Debt Instrument [Line Items]            
Proceeds from sale of business $ 35,000,000   35,000,000      
Term Loan | Line of Credit | Secured Debt            
Debt Instrument [Line Items]            
Debt instrument, face amount     250,000,000   $ 250,000,000  
Total debt     250,000,000      
Revolving Loans | Line of Credit | Revolving Credit Facility            
Debt Instrument [Line Items]            
Total debt     0      
Maximum borrowing capacity     100,000,000      
Maximum borrowing capacity, increase limit     125,000,000.0      
Maximum borrowing capacity, decrease limit     50,000,000.0      
Current borrowing capacity     $ 100,000,000